What is the price of the Indian version of the targeted drug Sotorasibu (AMG510)?

There is currently no Indian version of the original drug or generic version of Sotorazeb (AMG510), and Sotorazeb may be sold in India and other places. The original drug of Sotorasibu has been launched in many countries, such as the United States, the European Union, etc. It is understood that there are also countries overseas producing generic drugs of Sotorasibu. Its pharmaceutical ingredients are basically the same as those of the original drug. It is suitable for the treatment of adult patients with advanced non-small cell lung cancer whose cells have specific genetic changes. There may be slight differences in production specifications and prices. Common generic drug manufacturers include Laos Lucius Pharmaceutical Factory, Daxiong Pharmaceutical Factory, etc.

Sotoracib is a cancer drug used to treat non-small cell lung cancer that has a specific genetic change in the geneKRAS, known as "KRAS G12C." Sotorasiib is given when disease has progressed after systemic therapy (treatment that affects the entire body). Sotorasib contains the active substance sotorasib, a small molecule that specifically and irreversibly inhibits KRAS G12C through a unique interaction. This inhibitor traps KRASG12C in an inactive GDP-bound state via a similar mechanism to other KRAS G12C inhibitors. Preclinical studies have shown that sotorasiib inhibited nearly all detectable phosphorylation of extracellular signal-regulated kinase (ERK), a key downstream effector of KRAS, resulting in durable and complete tumor regression in mice with KRAS G12C tumors.

Since drug prices may change over time, the current price of the original version fluctuates between 40,000 to 80,000 yuan, and the price of the generic version may be more than 1,000 to 2,000 yuan (the price may fluctuate due to the exchange rate). Patients should choose formal channels when purchasing overseas drugs to ensure the quality and safety of the drugs.